Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).

被引：0

作者：

Krop, Ian E.

Masuda, Norikazu

Mukohara, Toru

Takahashi, Shunji

Nakayama, Takahiro

Inoue, Kenichi

Iwata, Hiroji

Toyama, Tatsuya

Yamamoto, Yutaka

Hansra, Damien Mikael

Takahashi, Masato

Osaki, Akihiko

Koyama, Kumiko

Inoue, Tatsuya

Yonekura, Takatoshi

Mostillo, Joseph

Ohwada, Shoichi

Tanaka, Yoshimi

Sternberg, David W.

Yonemori, Kan

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Nagoya Univ, Grad Sch Med, Nagoya, Japan

[3] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[4] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan

[5] Osaka Int Canc Inst, Osaka, Japan

[6] Saitama Canc Ctr, Saitama, Japan

[7] Aichi Canc Ctr Hosp, Nagoya, Japan

[8] Nagoya City Univ, Nagoya, Japan

[9] Kumamoto Univ Hosp, Kumamoto, Japan

[10] Piedmont Phys Med Oncol, Fayetteville, GA USA

[11] Natl Hosp Org, Hokkaido Canc Ctr, Sapporo, Japan

[12] Saitama Med Univ, Int Med Ctr, Saitama, Japan

[13] Daiichi Sankyo Co Ltd, Tokyo, Japan

[14] Daiichi Sankyo RD Novare Co Ltd, Edogawa Ku, Tokyo, Japan

[15] Daiichi Sankyo Inc, Basking Ridge, NJ USA

[16] Natl Canc Ctr, Tokyo, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1002

引用

页数：1